Olin Corporation reports Q1 2026 results on May 1 with short sellers in full retreat — yet the stock still can't catch a bid.
The most striking positioning move heading into the print is the collapse in short interest. SI % of Free Float dropped to 9.4%, down nearly 24% over the past month and off 17% on the week alone — with a single-session plunge of 16.5% on April 24 marking the steepest one-day cover in the recent period. Utilization has followed, falling to 7.8% from a 52-week high of 21.4%, and borrow costs remain negligible at 0.47%. That combination — bears covering aggressively, cheap borrow, ample availability — does not describe a crowded short thesis. It describes a position that has already been unwound. The ORTEX short score eased to 48.8 on April 24 from 53.4 a week earlier, confirming the de-risking trend. Options positioning is mildly more cautious: the put/call ratio nudged to 0.30, just above its 20-day average of 0.28, but at roughly one standard deviation above the mean this is a far cry from the elevated hedging levels seen ahead of other chemical sector prints this season. The stock itself closed at $26.83 on April 27, down 7.5% on the month, which goes a long way toward explaining why bears have less to fight for.
The debate is really about whether Olin's core chlor-alkali business can stabilise in a difficult demand environment. The bull case rests on price discipline in the chlor-alkali segment and the potential for caustic soda tightening in Q2 2026. Against that, the bear case points to elevated costs, weak demand in the CAPV and Winchester segments, stranded costs from ECU capacity closures, and a 2026 EBITDA estimate that has been trimmed to roughly $503M. EV/EBITDA of 9.2x has compressed by more than a full turn over the past month, suggesting the market is already discounting a soft quarter. EPS momentum is deeply negative — ranked in just the 4th percentile on a 30-day basis and the 2nd percentile on 90 days — while the analyst consensus differential ranks in the 93rd percentile, meaning the Street has materially more upside priced in than the current price implies. Recent analyst moves have been predominantly constructive: Wells Fargo upgraded to Overweight with a $35 target in early April, and Citigroup lifted its target to $30 from $26 on April 16, maintaining Neutral. UBS also raised its target to $29. All three actions came before the stock's further slide, and the mean target of ~$26.79 is now essentially at the current price — leaving almost no implied upside in the consensus.
On the ownership side, the institutional register is notably value-oriented. Hotchkis & Wiley holds 13.4% of shares and added nearly 2.6 million shares in the most recent reported period. Pzena and Dimensional both added meaningfully in Q1. The CEO sold roughly 20,000 shares in mid-March at $26.25 — close to current levels — though this followed a 50,000-share award in the same session, limiting its significance as a signal. Historical prints have been punishing on the day: the last earnings release in January saw the stock fall 8.5%, before recovering to end the five-day window up about 3%. The prior report triggered just a 0.8% drop on the day but an 11% five-day bounce. The pattern is one where the initial reaction tends to overshoot, and peers tell a mixed story heading in: DOW and TROX are up 8-11% on the week while WLK is slightly lower, suggesting sector sentiment is not uniformly negative.
The May 1 print will test whether the collapse in short interest reflects genuine confidence in a chlor-alkali recovery, or simply a lack of conviction on both sides of a stock that has reset valuation but not yet found a new earnings floor.
See the live data behind this article on ORTEX.
Open OLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
